These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21228582)

  • 21. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibiotics dosing strategies in chronic kidney disease].
    Bourquin V
    Rev Med Suisse; 2007 Oct; 3(128):2280-2, 2284-8. PubMed ID: 17985604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dosage of drugs in patients with kidney diseases].
    Kokot F
    Wiad Lek; 1996; 49(7-12):87-91. PubMed ID: 9245115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
    Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
    G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic Issues in treating hypertension in CKD.
    Sica DA
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):42-7. PubMed ID: 21224029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.
    López-Novoa JM; Martínez-Salgado C; Rodríguez-Peña AB; López-Hernández FJ
    Pharmacol Ther; 2010 Oct; 128(1):61-81. PubMed ID: 20600306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.
    Hermsen ED; Maiefski M; Florescu MC; Qiu F; Rupp ME
    Pharmacotherapy; 2009 Jun; 29(6):649-55. PubMed ID: 19476418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to optimize drug delivery in renal replacement therapy.
    Awdishu L; Bouchard J
    Semin Dial; 2011; 24(2):176-82. PubMed ID: 21517984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.
    Bacchus S; O'Mara N; Manley H; Fishbane S
    Ann Pharmacother; 2009 Nov; 43(11):1857-66. PubMed ID: 19826095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment for chronic kidney disease service in high-risk patients at community health clinics.
    Patel HR; Pruchnicki MC; Hall LE
    Ann Pharmacother; 2005 Jan; 39(1):22-7. PubMed ID: 15546945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.
    Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K
    J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing pediatric dosing: a developmental pharmacologic approach.
    Anderson GD; Lynn AM
    Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatitis C virus and chronic progressive kidney disease].
    Kes P; Slavicek J
    Acta Med Croatica; 2009 Dec; 63(5):431-6. PubMed ID: 20198903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse safety events in patients with Chronic Kidney Disease (CKD).
    Offurum A; Wagner LA; Gooden T
    Expert Opin Drug Saf; 2016 Dec; 15(12):1597-1607. PubMed ID: 27648959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current state of knowledge on age, sex, and their interactions on clinical pharmacology.
    Schwartz JB
    Clin Pharmacol Ther; 2007 Jul; 82(1):87-96. PubMed ID: 17495875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.
    Heintz BH; Matzke GR; Dager WE
    Pharmacotherapy; 2009 May; 29(5):562-77. PubMed ID: 19397464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.